Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from the National Medical Products Administration (NMPA) in China for a clinical trial filing of its pipeline candidate, SKB518. The novel antibody-drug conjugate (ADC) is slated for assessment in patients with general advanced solid tumors.
Developed through Kelun-Biotech’s proprietary OptiDC platform technology, SKB518 has demonstrated a promising efficacy and safety profile in pre-clinical studies. The company is actively progressing the development of over 10 pre-clinical ADCs and innovative conjugated technology drug assets in parallel.- Flcube.com
